Cytek Biosciences reported 6% year-over-year revenue growth for the second quarter of 2026, according to highlights from the company’s earnings call. The result reflects uneven performance across its key geographic markets.
Revenue gains in the United States and China reached double-digit levels, providing the main support for the quarter’s overall increase. These markets helped counter slower conditions elsewhere.
Cytek said continued weakness in Europe and parts of the Asia-Pacific region limited its broader growth rate. As a result, the company’s international performance remained mixed despite stronger demand in the United States and China.
